利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.017 秒)

    USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN
    2.
    发明申请
    USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN 有权
    二甲双胍在治疗慢性疼痛中的应用

    公开(公告)号：US20110251250A1

    公开(公告)日：2011-10-13

    申请号：US13166088

    申请日：2011-06-22

    申请人： Carlo FARINA ,  Carla Ghelardini ,  Paola Petrillo

    发明人： Carlo FARINA ,  Carla Ghelardini ,  Paola Petrillo

    IPC分类号： A61K31/4188 ,  A61P25/04 ,  A61P19/02

    CPC分类号： A61K31/7068 ,  A61K31/4188 ,  A61K31/555 ,  A61K45/06 ,  A61K2300/00

    摘要： The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

    摘要翻译： 公开了使用二拉西坦治疗慢性疼痛。 在比以前公开的与其认知增强活性（即改善学习和记忆）相比更高的剂量下，双拉西坦能够完全恢复与慢性疼痛的几种动物模型相关的痛觉过敏或异常性疼痛。 二西拉西坦在与抗病毒和化疗药物治疗相关的医源性神经病变以及由骨关节炎引起的疼痛状况下表现出高活性。 此外，即使在比最高治疗剂量高10倍的剂量下，二西拉坦也没有毒性。 因此公开了用高效和基本上无毒化合物治疗这种衰弱病态的可能性。

    Use of dimiracetam in the treatment of chronic pain
    3.
    发明授权
    Use of dimiracetam in the treatment of chronic pain 有权
    使用双拉西坦治疗慢性疼痛

    公开(公告)号：US07989421B2

    公开(公告)日：2011-08-02

    申请号：US12450944

    申请日：2008-04-15

    申请人： Carlo Farina ,  Carla Ghelardini ,  Paola Petrillo

    发明人： Carlo Farina ,  Carla Ghelardini ,  Paola Petrillo

    IPC分类号： A61K31/44 ,  A61K31/40 ,  A61P23/00

    CPC分类号： A61K31/7068 ,  A61K31/4188 ,  A61K31/555 ,  A61K45/06 ,  A61K2300/00

    摘要： The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

    摘要翻译： 公开了使用二拉西坦治疗慢性疼痛。 在比以前公开的与其认知增强活性（即改善学习和记忆）相比更高的剂量下，二西拉坦能够完全恢复与慢性疼痛的几种动物模型相关的痛觉过敏或异常性疼痛。 二西拉西坦在与抗病毒和化疗药物治疗相关的医源性神经病变以及由骨关节炎引起的疼痛状况下表现出高活性。 此外，即使在比最高治疗剂量高10倍的剂量下，二西拉坦也没有毒性。 因此公开了用高效和基本上无毒化合物治疗这种衰弱病态的可能性。

    USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN
    5.
    发明申请
    USE OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN 有权
    二甲双胍在治疗慢性疼痛中的应用

    公开(公告)号：US20100129469A1

    公开(公告)日：2010-05-27

    申请号：US12450944

    申请日：2008-04-15

    申请人： Carlo Farina ,  Carla Ghelardini ,  Paola Petrillo

    发明人： Carlo Farina ,  Carla Ghelardini ,  Paola Petrillo

    IPC分类号： A61K33/24 ,  A61K31/4188 ,  A61K31/437 ,  C07D487/04 ,  A61P25/02 ,  A61P25/00

    CPC分类号： A61K31/7068 ,  A61K31/4188 ,  A61K31/555 ,  A61K45/06 ,  A61K2300/00

    摘要： The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

    摘要翻译： 公开了使用二拉西坦治疗慢性疼痛。 在比以前公开的与其认知增强活性（即改善学习和记忆）相比更高的剂量下，二西拉坦能够完全恢复与慢性疼痛的几种动物模型相关的痛觉过敏或异常性疼痛。 二西拉西坦在与抗病毒和化疗药物治疗相关的医源性神经病变以及由骨关节炎引起的疼痛状况下表现出高活性。 此外，即使在比最高治疗剂量高10倍的剂量下，二西拉坦也没有毒性。 因此公开了用高效和基本上无毒化合物治疗这种衰弱病态的可能性。

    Use of dimiracetam in the treatment of chronic pain
    8.
    发明授权
    Use of dimiracetam in the treatment of chronic pain 有权
    使用双拉西坦治疗慢性疼痛

    公开(公告)号：US08222241B2

    公开(公告)日：2012-07-17

    申请号：US13166088

    申请日：2011-06-22

    申请人： Carlo Farina ,  Carla Ghelardini ,  Paola Petrillo

    发明人： Carlo Farina ,  Carla Ghelardini ,  Paola Petrillo

    IPC分类号： A61K31/44 ,  A61K31/40 ,  A61P23/00

    CPC分类号： A61K31/7068 ,  A61K31/4188 ,  A61K31/555 ,  A61K45/06 ,  A61K2300/00

    摘要： The use of dimiracetam in the treatment of chronic pain is disclosed. At doses higher than those previously disclosed in relation with its cognition enhancing activity (i.e. amelioration of learning and memory), dimiracetam was able to completely revert hyperalgesia or allodynia associated with several animal models of chronic pain. Dimiracetam showed high activity in iatrogenic neuropathies associated with antiviral and chemotherapeutic drug treatments and in painful conditions caused by osteoarthritis. In addition, dimiracetam was devoid of toxicity even at doses 10-fold higher than the highest therapeutic dose. The possibility of treating such debilitating pathologies with a highly effective and essentially non-toxic compound is therefore disclosed.

    摘要翻译： 公开了使用二拉西坦治疗慢性疼痛。 在比以前公开的与其认知增强活性（即改善学习和记忆）相比更高的剂量下，二西拉坦能够完全恢复与慢性疼痛的几种动物模型相关的痛觉过敏或异常性疼痛。 二西拉西坦在与抗病毒和化疗药物治疗相关的医源性神经病变以及由骨关节炎引起的疼痛状况下表现出高活性。 此外，即使在比最高治疗剂量高10倍的剂量下，二西拉坦也没有毒性。 因此公开了用高效和基本上无毒化合物治疗这种衰弱病态的可能性。